2-amino-N-(2-(3-fluorophenyl)-2-oxoethyl)benzamide | 1219730-00-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-amino-N-(2-(3-fluorophenyl)-2-oxoethyl)benzamide
• 英文别名: 2-amino-N-[2-(3-fluorophenyl)-2-oxoethyl]benzamide
• CAS: 1219730-00-3
• 化学式: C₁₅H₁₃FN₂O₂
• 分子量: 272.279
• InChiKey: MOPMNIZRAAPYPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  72.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-amino-N-(2-(3-fluorophenyl)-2-oxoethyl)benzamide 在 sodium carbonate 作用下， 反应 2.0h， 以93%的产率得到3-amino-2-(3-fluorophenyl)quinolin-4-ol
  参考文献：
  名称：

  New 1,3-oxazolo[4,5-c]quinoline derivatives: Synthesis and evaluation of antibacterial and antituberculosis properties

  摘要：

  A new class of fused oxazoloquinoline derivatives was synthesized starting from 2-bromo-1-phenylethanones 1a-b through multi-step reactions. The newly synthesized compounds were evaluated for their in vitro antibacterial against Escherichia coli (ATTC-25922), Staphylococcus aureus (ATTC-25923), Pseudomonas aeruginosa (ATCC-27853) and Klebsiella pneumoniae (recultured) and antituberculosis activity against Mycobacterium tuberculosis H37Rv (ATCC 27294). Preliminary results indicated that most of the compounds demonstrated very good antibacterial and antituberculosis activities which are comparable with the first line drugs. Compounds 6a, 6c, 6g, 6j, 6k and 6n emerged as the lead antitubercular agents with MIC, 1 mu g/mL and 99% bacterial inhibition while eight compounds, viz.. 5a, 15k, 6a, 6c, 6g, 6j, 6k and 6n were found to be more potent than INN (MIC: 1.5 mu g/mL) with MIC 1 mu g/mL. (C) 2009 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2009.11.036
• 作为产物：
  描述：

  3-氟溴代苯乙酮 在 乌洛托品 、 sodium carbonate 作用下， 以 氯仿 、 水 为溶剂， 反应 7.17h， 生成 2-amino-N-(2-(3-fluorophenyl)-2-oxoethyl)benzamide
  参考文献：
  名称：

  苯二氮卓类脑穿透性PARP-1抑制剂的设计与合成

  摘要：

  摘要 聚 (ADP-核糖) 聚合酶 (PARP) 抑制剂在癌症治疗中起着至关重要的作用。然而，大多数批准的 PARP 抑制剂不能穿过血脑屏障，从而限制了它们在中枢神经系统中的应用。在这里，设计并合成了 55 种苯二氮卓类药物来筛选脑穿透性 PARP-1 抑制剂。评估所有目标化合物的 PARP-1 抑制活性，并选择具有更好活性的化合物进行进一步的体外测定。其中，化合物H34、H42、H48和H52对乳腺癌细胞表现出可接受的抑制作用。此外，计算预测与体外渗透性测定和体内证明我们合成的苯二氮卓类PARP-1抑制剂具有脑渗透性。化合物H52表现出比 Rucaparib 高 40 倍的 B/P 比率，将被选择用于开发其在神经退行性疾病中的潜在用途。我们的研究为开发脑穿透性 PARP-1 抑制剂提供了潜在的先导化合物和设计策略。 强调 结构融合用于筛选脑穿透 PARP-1 抑制剂。 评估了 55 种苯二氮卓类药物的

  DOI：

  10.1080/14756366.2022.2053524

文献信息

• Design and synthesis of benzodiazepines as brain penetrating PARP-1 inhibitors
  作者：Jiang Yu、Wenfeng Gou、Haihua Shang、Yating Cui、Xiao Sun、Lingling Luo、Wenbin Hou、Tiemin Sun、Yiliang Li

  DOI：10.1080/14756366.2022.2053524

  日期：2022.12.31

  (ADP-ribose) polymerase (PARP) inhibitors play a crucial role in cancer therapy. However, most approved PARP inhibitors cannot cross the blood-brain barrier, thus limiting their application in the central nervous system. Here, 55 benzodiazepines were designed and synthesised to screen brain penetrating PARP-1 inhibitors. All target compounds were evaluated for their PARP-1 inhibition activity, and compounds

  摘要 聚 (ADP-核糖) 聚合酶 (PARP) 抑制剂在癌症治疗中起着至关重要的作用。然而，大多数批准的 PARP 抑制剂不能穿过血脑屏障，从而限制了它们在中枢神经系统中的应用。在这里，设计并合成了 55 种苯二氮卓类药物来筛选脑穿透性 PARP-1 抑制剂。评估所有目标化合物的 PARP-1 抑制活性，并选择具有更好活性的化合物进行进一步的体外测定。其中，化合物H34、H42、H48和H52对乳腺癌细胞表现出可接受的抑制作用。此外，计算预测与体外渗透性测定和体内证明我们合成的苯二氮卓类PARP-1抑制剂具有脑渗透性。化合物H52表现出比 Rucaparib 高 40 倍的 B/P 比率，将被选择用于开发其在神经退行性疾病中的潜在用途。我们的研究为开发脑穿透性 PARP-1 抑制剂提供了潜在的先导化合物和设计策略。 强调 结构融合用于筛选脑穿透 PARP-1 抑制剂。 评估了 55 种苯二氮卓类药物的
• New 1,3-oxazolo[4,5-c]quinoline derivatives: Synthesis and evaluation of antibacterial and antituberculosis properties
  作者：Sumesh Eswaran、Airody Vasudeva Adhikari、R. Ajay Kumar

  DOI：10.1016/j.ejmech.2009.11.036

  日期：2010.3

  A new class of fused oxazoloquinoline derivatives was synthesized starting from 2-bromo-1-phenylethanones 1a-b through multi-step reactions. The newly synthesized compounds were evaluated for their in vitro antibacterial against Escherichia coli (ATTC-25922), Staphylococcus aureus (ATTC-25923), Pseudomonas aeruginosa (ATCC-27853) and Klebsiella pneumoniae (recultured) and antituberculosis activity against Mycobacterium tuberculosis H37Rv (ATCC 27294). Preliminary results indicated that most of the compounds demonstrated very good antibacterial and antituberculosis activities which are comparable with the first line drugs. Compounds 6a, 6c, 6g, 6j, 6k and 6n emerged as the lead antitubercular agents with MIC, 1 mu g/mL and 99% bacterial inhibition while eight compounds, viz.. 5a, 15k, 6a, 6c, 6g, 6j, 6k and 6n were found to be more potent than INN (MIC: 1.5 mu g/mL) with MIC 1 mu g/mL. (C) 2009 Elsevier Masson SAS. All rights reserved.